Pleural Effusion, Malignant Clinical Trial
Official title:
The Effect on Respiratory Function of Monitored Anesthesia Care With Dexmedetomidine in Patients Undergoing Diagnostic or Therapeutic Pleuroscopy
The primary objective of this prospective trial will be to assess the effects of dexmedetomidine administration on oxygenation and respiratory function in patients undergoing diagnostic or therapeutic medical thoracoscopy/pleuroscopy for a pleural effusion compared to conventional conscious sedation/monitored anesthesia care (MAC) with midazolam. The secondary endpoint of the study will be to also assess the effects of dexmedetomidine administration on respiratory mechanics and postprocedural complications
The study will be conducted at the Department of Anesthesiology and Pain Management in
collaboration with the Department of Thoracic Surgery at the Attikon University Hospital,
Athens.
The trial has received approval by the Attikon University Hospital's Scientific & Bioethics
Committee and written informed consent will be obtained from all patients enrolled in the
study.
Sample Size Calculation: A total of 60 patients will be assigned on a 1 to 1 basis to avoid
bias to either a "DEX = dexmedetomidine" (n=30) or a "MIDAZOLAM/FENTANYL" group (n=30). To
determine the required sample sizes quoted above, the statistical G-power calculator
developed by Faul, Erdfelder, Lang, and Buchner was used. Values used to calculate the effect
size (e=0.9326031) are based on results previously reported in the literature. For a study
power of 90% with an alpha value of 0.05, a total of 26 patients in each group will need to
be enrolled. Factoring in possible losses this number was rounded up to 30 patients per
group.
Main Measurements Performance & Methods: Patients will initially be assessed with spirometry
and arterial blood gas (ABG) analysis prior to the medical thoracoscopy/pleuroscopy to
determine their baseline values of Forced Expiratory Volume in 1 second (FEV1), Forced Vital
Capacity (FVC) and Partial arterial Pressure of Oxygen/ Fraction of Inspiratory Oxygen
(PaO2/FiO2) ratio respectively. Intra-operatively repeat ABG analysis will be performed at 30
minutes following the start of administration of the study drug. Subsequent to their medical
thoracoscopy/pleuroscopy procedure study subjects will remain in the Post Anesthesia Care
Unit (PACU) for a minimum of 1 hour following the discontinuation of the study drug. Repeated
ABG analysis and spirometry will be carried out at that 1 hour to assess improvement over the
pre-operative values. The administration of the spirometry exam will be by the same
pulmonologist using the same spirometer device so as to minimize inter-observer variability.
Arterial blood gas measurements will also be performed in the same analysis device.
Protocol for Sedation & Analgesia: Dexmedetomidine (DEX) group: Initial loading dose of
dexmedetomidine will be 1.0 μg/kg of dexmedetomidine administered over 10 minutes. Fifteen
minutes after starting the study drug administration, patients will be assessed for their
level of sedation using the Observer's Assessment of Alertness/Sedation Scale (OAA/S), and
any patient having a score ≥3 will receive intravenous (IV) midazolam in 0.5 mg doses, which
will be repeated until the OAA/S is ≤2. MIDAZOLAM/FENTANYL group: Patients will be assessed
for their level of sedation using the Observer's Assessment of Alertness/Sedation Scale
(OAA/S), and any patient having a score ≥3 will receive intravenous (IV) midazolam in 0.5 mg
doses, which will be repeated until the OAA/S is ≤2 All subjects will receive local
anesthesia prior to the commencement of the "open" trocar insertion technique performed by
the thoracic surgeon at the point of introduction of the rigid trocar in the pleural cavity
with a combination of lidocaine 1.5% and ropivacaine 0.75%. If a patient is not adequately
sedated, rescue midazolam will be administered as single IV boluses of 0.5 mg, which will be
repeated as needed to achieve an OAA/S score of ≤3. Intravenous fentanyl, 25 μg boluses which
can be repeated as necessary, will be given if a patient expresses a pain score of ≥3 during
the study drugs infusion and ≥4 in the PACU on a Verbal scale of 0-10 (0 = no pain, 10 =
worst pain), or if the anesthetist determines the presence of pain when verbal communication
is not possible. Blood gas analysis will be obtained at 30' and 60' minutes intraoperatively.
The dexmedetomidine infusion will be discontinued after wound closure.
At any time, if clinically indicated, the patient will be converted to an alternative
sedative or anesthetic therapy and the study will be discontinued. OAA/S scores and all
standard vital signs will be obtained every 5 min throughout the study drug infusion and
before the administration of any rescue midazolam.
The time to reach OAA/S =5 from the end of infusion will be recorded. Other data recorded at
the end of surgery will include total fentanyl and midazolam used intraoperatively,
crystalloid infusion in litres, total mcg of the study drug (provided a [dex] = 4 mcg/ml) and
postoperative Visual Analogue Scale (VAS) pain score. If VAS>3 acetaminophen 1 g will be
administered. The patient's monitoring will be continued in the post-anesthesia care unit
(PACU) with vital signs been recorded every 5 minutes for the first 15 minutes, then every 15
minutes for the next 45 minutes. Blood gas analysis will be obtained every 30' until
discharge from the PACU. At 24 hours from the end of surgery, a spirometry will be performed.
Patient satisfaction and surgeon satisfaction score will also be registered (4-point scale -
0 min to 3 max). Patients will be discharged from the PACU when their OAA/S score =5.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05693727 -
Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
|
||
Recruiting |
NCT05910112 -
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
|
||
Completed |
NCT03270215 -
The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion
|
||
Completed |
NCT03272997 -
The Value of PET-CT in Pleural Effusions
|
||
Completed |
NCT00099541 -
Non-small Cell Lung Cancer Registry
|
Phase 4 | |
Recruiting |
NCT04844827 -
Pleural Carcinomatosis Tissue Banking
|
||
Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
Recruiting |
NCT05278975 -
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT02407912 -
Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer
|
N/A | |
Terminated |
NCT00316134 -
Multiple Biomarkers in Undiagnosed Pleural Effusion
|
N/A | |
Not yet recruiting |
NCT06275178 -
Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
|
||
Recruiting |
NCT04684459 -
Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis
|
Early Phase 1 | |
Recruiting |
NCT04670562 -
Longitudinal Follow up of Patients With Pleural Effusion
|
||
Not yet recruiting |
NCT02805062 -
Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy
|
N/A | |
Completed |
NCT03276715 -
Prognostic Factors on Malignant Pleural Effusion
|
||
Completed |
NCT03394105 -
Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
Terminated |
NCT02702700 -
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
|
Phase 1 | |
Recruiting |
NCT02045121 -
Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management
|
N/A | |
Completed |
NCT01670786 -
Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion
|
Phase 4 |